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Objective: We hypothesized that atheroemboli released during renal angioplasty could be responsible for the modest
functional result of renal angioplasty even after anatomic reduction of renal artery stenosis. To test this hypothesis, we
enumerated and sized fragments released during ex vivo angioplasty and stenting of human renal artery atherosclerotic
specimens removed during aortorenal endarterectomy.
Methods: Thirty-three intact aortorenal atheroma specimens (16 pairs with adjacent aortic atheroma and one specimen
with a single renal artery orifice) were removed from 17 patients with renal artery occlusive disease who underwent renal
artery endarterectomy. specimens. Endarterectomy specimens were removed with a ring of aortic plaque and “fitted” with
a polytetrafluoroethylene “adventitia”. Ex vivo angioplasty was technically successful in 31 of the 33 specimens and was
performed by using a 0.018-inch guidewire and 3.0-mm and 5.0-mm angioplasty balloons inflated for 30 seconds at 15
atmospheres pressure. Stenting was performed with either a 5-mm or 6-mm self-expanding Wallstent. Each artery was
flushed with 20 mL of saline after guidewire placement, each angioplasty, and stent placement. The effluent was collected
for analysis for counting with either a microscope (size>100 m) or a Coulter counter (size<100 m). The number and
size of embolic fragments in the effluent collected after each manipulation was recorded.
Results: Each manipulation of the specimens, including simply advancing the guidewire through the atherosclerotic
lesion, released thousands of fragments. The numbers of fragments in each size category increased with decreasing particle
size. Positioning and deploying the Wallstent released an additional bolus of fragments similar to that released after
balloon angioplasty.
Conclusions: Ex vivo renal angioplasty releases thousands of atherosclerotic fragments of sufficient size to create vascular
occlusions and initiate significant renal parenchymal damage. The results of renal angioplasty procedures could be
improved by placing distal protection devices to prevent atheroembolization. (J Vasc Surg 2005;41:1026-30.)
Clinical Relevance: Athero-emboli produce a local arteritis in the kidney and could cause substantial damage to the renal
parenchyma. This report explores the quantity of athero-emboli released during ex vivo angioplasty and stenting of renal
atheroma specimens. The number of emboli found in this ex vivo study suggest that the use of protection devices may be
advisable to protect the end organ, as done with angioplasty of the carotid artery. Of necessity, this was an ex vivo study
and direct application to the clinical setting will need further study. Fortunately, multi-center trials examining the value
of protection devices are currently in progress.Occlusive lesions from renal artery atherosclerosis are the
most common cause of secondary hypertension, accounting
for 5% of all cases of hypertension in the United States.1 If
untreated, renal artery occlusive disease (RAOD) leads to
ischemic nephropathy and may account for 14% of all new
patients starting dialysis programs each year.2 The outlook for
patients suffering from end-stage renal disease secondary to
RAOD is particularly dismal, with an expected 5-year survival
of 18% and 10-year survival of 5%.3 These data form the basis
for current treatment recommendations for RAOD in the
absence of randomized clinical trial data demonstrating ben-
efits in survival or freedom from dialysis.
Direct surgical renal revascularization has been demon-
strated to be effective treatment for RAOD, in noncontrolled
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1026investigations, to improve renal function and life expec-
tancy.4-7 However, the significant morbidity and mortality
associated with open surgical procedures has prompted inter-
est in renal artery angioplasty and stenting as an alternative
with less morbidity. Despite the technical success achievable
with renal artery angioplasty/stenting, the degree of benefit
gained for patients with severe hypertension and/or ischemic
nephropathy has been less than reported in series of open
surgical renal artery revascularizations.8-10 The control of
hypertension may be improved by angioplasty and stenting
but hypertensive cure is rare and results are frequently not
durable.11-17 Furthermore, the data concerning renal func-
tional improvement following angioplasty is mixed with the
incidence of improvement reported at only 15% to 25% and
actual worsening of renal function reported in a significant
proportion of patients.18-21 The frequent absence of clinical
benefit following technically successful renal angioplasty does
not coincide with the nephropathy caused by contrast agents
and may occur when renal artery diameter appears fully re-
stored.
Poor patient selection and unsuspected irreversibility of
existing renal parenchymal damage are other factors that
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potential explanation is embolization of atheroembolic frag-
ments during the angioplasty procedure.22,23 Atheroemboli
to the kidney are known to initiate a localized arteritis result-
ing in renal dysfunction presenting days to weeks after the
procedure, which is consistent with the timing of the renal
insufficency that may be observed after angioplasty.24 After
examining the clinical course of patients undergoing renal
artery angioplasty, we hypothesized that angioplasty and
stenting of renal artery atherosclerosis releases thousands of
atherosclerotic fragments into the renal parenchyma, a phe-
nomenon that we have observed after angioplasty of the
carotid artery.25,26 To test our hypothesis, we performed ex
vivo angioplasty on human renal artery atherosclerotic speci-
mens removed during aorto-renal endarterectomy from pa-
tients with RAOD. The enumeration and sizing of fragments
released during these procedures comprises this report.
METHODS
Demographics
Thirty-three intact aorto-renal artery atheroma specimens
were removed from 17 patients with RAOD who underwent
renal artery endarterectomy on the Vascular Surgery Services
at Wake Forrest University and the San Francisco Veterans
Affairs Hospital (University of California, San Francisco). The
group consisted of thirteen men and four women with an
average age of 69 years (range 58-73 years). The mean pre-
senting blood pressure measurements were a systolic pressure
of 183 26 mmHg and a diastolic pressure of 94 17 mm
Hg. Fourteen of the patients had an elevated serum creatinine
level (1.4mg%).Themean creatinine level for the groupwas
2.9  4.3 mg% and one patient was on hemodialysis at the
time of operation (Table I).
Renal endarterectomy specimens
The mean angiographic percent stenosis of the endar-
Table I. Patient characteristics
Age Gender
Pre Op
Cr
Post Op
Cr
% Stenosis R
renal*
% Stenosis L
renal*
71 M 2.3 1.6 80 80
66 M 2.4 1.2 90 100
74 F 15.4 1.1 80 100
68 F 1.8 1.5 90 90
67 M 2.6 1.8 80 80
74 M 2.0 1.3 90 100
68 M 1.8 1.5 50 100
73 F 1.3 1.3 100 80
71 M 0.9 0.8 80 80
72 M 1.1 0.7 80 80
61 M 2.0 1.0 70 90
67 F 3.9 3.0 100 80
70 M 2.2 2.0 60 80
58 M 4.8 2.0 90 60
73 M 1.7 3.0 80 80
69 M 2.2 3.0 80 80
72 M 1.7 2.0 70 80
*Estimated by angiographyterectomy specimens was 83%  11%. Endarterectomyspecimens were removed with a ring of aortic plaque (Fig-
ure 1). Specimens were washed, placed in saline, and refrig-
erated until the ex vivo angioplasty/stenting was per-
formed 3-5 days after surgery.
Polytetrafluoroethylene (PTFE) vascular grafts (W.L.
Gore and Associates, Flagstaff, AZ) were cut open longitu-
dinally, and their outer reinforcing wraps removed. After a
PTFE aortic graft (14-18 mm) was fashioned to fit the
contour of the aortic specimen, “orifices” were cut to
accommodate the renal arteries. The PTFE “renal arteries”
were sutured to the aortic graft to cover the renal artery
atheroma extracted from the renal arteries . The entire
specimen was then blotted dry, dotted with adhesive, and
placed into the lumen of the tailored PTFE graft. The aortic
graft was then sutured closed with a 6-0 PTFE suture on a
7-0 needle (W.L. Gore and Associates). The suture lines
were coated with adhesive to minimize leakage (Figure 2).
Ex vivo angioplasty
Ex vivo angioplasty of the renal arteries was performed
following procedural techniques established by the Depart-
Fig 1. Renal artery endartectomy specimen with associated cylin-
der of aortic atheroma.
Fig 2. PTFE “jacket” around the atheroma. The suture lines
were coated with tissue glue to minimize leakage.ment of Interventional Radiology at the University of Cal-
ts. (O
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were performed at 37o C and flushed out through the
respective PTFE graft housing that artery atheroma. Each
wrapped specimen was held in place with a paddedmovable
brace and initially flushed with 10 mL of saline which was
discarded. A 0.018-inch guide wire was used to cannulate
each renal artery specimen. Cannulating the renal arteries
was facilitated by the short PTFE “aorta” which could be
moved so that the guidewire could be directly inserted into
the renal orifice. Those arteries which were stented were
cannulated and stents placed with the help of fluoroscopy
and a non-ionic contrast agent. While one renal atheroma
was being cannulated and angioplasty performed, the other
was clamped by occluding the PTFE “renal artery” beyond
the atheroma. The initial angioplasty was performed with a
3.0mmballoon, and the second angioplasty was performed
with a 5.0 mm balloon (Medi-tech, Incorporated, Water-
town, MA). Both balloons were inflated for 30 seconds
duration at 15 atm. The artery was flushed with 20 mL of
saline after guide wire placement and after each angioplasty.
The effluent was saved for analysis. Prior to angioplasty of
the second artery, an additional flush of 20mL of saline was
done and the effluent discarded.
Stenting was performed in seven specimens using a
self-expanding Wallstent (Schneider USA, Inc., Minneap-
olis, MN) and the specimen was washed a third time with
20 mL of saline. Prior to stent placement balloon angio-
plasty was performed with both a 3.0 mm and 5.0 mm
balloon. Four of the stents deployed were 5mm in diame-
ter, while three stents were 6mm in diameter. There was no
additional angioplasty to improve renal artery luminal cou-
tour after stent placement.
Collection and analysis of embolic fragments
The effluent was collected in 20 mL conical centrifuge
tubes after each manipulation. The effluent was centrifuged
at 20,000 g for 20 minutes, the saline decanted, and the
particulates re-suspended in 500 microliters of fresh saline.
The number and size of embolic fragments in the effluent
were examined under a microscope at 100 x magnification
with a 100 m background grid and categorized in incre-
ments of 100 m.
We examined the number of atherosclerotic fragments
less than 100 m in eight of the renal artery specimens. In
these cases, after angioplasty the effluent was divided into
two portions. One portion was used for counting fragments
under 100 mwith a Coulter counter equipped with a 200
Table II. Fragments released from ex-vivo renal arteries a
Manipulation 100-200 m
Guide Wire (n  31) 59.3  49.9
1st balloon (n  31) 73.6  69.2
2nd balloon (n  31) 77.6  61.1
Total (n  31) 210.4  163.8
*Ex-vivo renal arteries PTA were done in 31 renal arteries from 17 patien
cannulated in two specimens)m filter. The other was processed as described above.RESULTS
Ex vivo renal angioplasty
There were 33 renal artery orifices removed during
surgery (16 pairs with adjacent aortic atheroma and one
from a single renal artery orifice). Our ex vivo angioplasty
was technically successful in 31 (94%) specimens. The
remaining two renal arteries were occluded and attempts to
pass the guide wire through the orifices were unsuccessful.
Fragments released during angioplasty/stenting
As seen in previous reports of ex vivo angioplasty, there
was considerable variation in the number of fragments
released from each plaque. Simply advancing the guide wire
through the atherosclerotic lesion caused fragments to be
dislodged in all specimens and large numbers of fragments
were released with every additional manipulation. The
number and size of fragments released during each manip-
ulation is shown in Table II for particulates greater than
100 m and in Table III for fragments less than 100 m.
There were only a few plaque fragments that were over
1mm in size. However, The number of fragments increased
with decreasing particle size. There were hundreds of frag-
ments in the 100-500 m range which would lodge in the
distal arterial tree and greater than 10,000 fragments in the
20-40m size category, the approximate size of the human
afferent arteriole (Table III).
The manipulation required to position and deploy the
self expanding Wallstent released another bolus of frag-
ments similar to that released after balloon angioplasty
(Table IV).
DISCUSSION
The success of catheter-based angioplasty and stenting
for both coronary artery and common iliac artery lesions
has translated into application of these techniques to other
atherosclerotic lesions, such as in the renal arteries. How-
ever, the functional outcome after renal artery angioplasty
has not matched the generally excellent anatomic outcome.
Few patients who undergo renal angioplasty for treatment
of hypertension have been shown in published trials to have
experienced a significant benefit.11,12 A recently published
meta-analysis comparing the effects of renal artery angio-
plasty and drug therapy in hypertensive patients demon-
strated only modest improvement in blood pressure with
angioplasty, achieving a mean reduction of 7 mmHg for
systolic blood pressure and 3 mmHg for diastolic blood
lasty. Size 100 m
0-500 m 500-1000 m 1 mm
.3  27.4 6.4  7.3 1.7  2.2
.3  38.1 8.5  9.2 2.2  2.7
.6  39.2 9.7  9.9 3.2  3.2
.5  87.8 24.5  22.6 7.0  6.6
ne specimen had one renal artery only and only one renal artery could bengiop
20
34
38
44
117pressure.16 Renal angioplasty in patients with ischemic
,020
6
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has been even more controversial. Often, only minimal
improvement in renal function has been reported, with
some patients experiencing a deterioration of renal func-
tion.20,27 These results stand in contrast to those published
after open surgical renal revascularization.28-32
Our data suggest that atheroembolization of the kidney
during the procedure could contribute to the disappointing
results after renal artery angioplasty. Atheroembolic renal
disease is a well described entity that can occur spontane-
ously or can be caused by atherosclerotic debris released by
surgical manipulation, vascular interventions with angio-
graphic catheters, or occasionally with the use of anticoagu-
lants and thrombolytic agents.33,34 These fragments can
cause acute occlusions but it is their late sequela, a localized
inflammation with intimal thickening and cellular prolifer-
ation, that is the most damaging.35 Atheroemboli create a
perivascular inflammatory response which is indistinguish-
able from the late appearance of arteritis. Thus, renal failure
due to procedure-induced atheroemboli is characterized by
a slow decline in renal function over 3 to 8 weeks,24 unlike
contrast-induced nephropathy, which presents earlier and
often resolves within 2 to 3 weeks. Furthermore, athero-
embolic renal artery disease is highly morbid.36,37A pro-
spective evaluation of patients with athero-embolic renal
disease demonstrated a mortality of 38% (36/95 patients),
while 23/95 (24%) patients developed end-stage renal
disease. As expected, patients with pre-existing chronic
renal impairment had an increased likelihood of progress-
ing to end-stage renal disease.38
Our results indicate that ex vivo renal angioplasty re-
leases hundreds of atherosclerotic fragments greater than
100 m in size, thousands that are of sufficient size to
occlude the glomerulus’ afferent arteriole and tens of thou-
sands which could lodge in capillary sized vessels and
initiate a focal inflammatory response. In a kidney with
millions of functioning glomeruli, this level of injury may
be well tolerated but in the presence of pre-existing renal
Table III. Fragments released from ex-vivo renal artery an
Size 100 m 10 m 10-
Guide Wire n  8 1,265,348  1,093,359 27,039
1st balloon n  8 780,187  515,886 16,407
2nd balloon n  8 942,284  1,413,177 16,574
Total 2,987,855 60
Table IV. 100 m fragments released from ex-vivo rena
Manipulation 100-200 m
Guide Wire (n  7) 50.4  17.6
1st balloon (n  7) 35.7  29.8
2nd balloon (n  7) 39.4  47.0
Stent Placement (n  7) 30.1  17.4
Total (n  7) 143.6  99.9disease, it could be devastating. Technique may be animportant factor as guide wire manipulation in the ex vivo
specimens often released as many fragments as angioplasty.
Guide wire passage was less traumatic in the ex vivo carotid
angioplasty model probably due to the ‘in line’ position of
the stenosis.25
Our experimental protocol can only approximate the
practice of renal angioplasty in the clinical setting. While we
believe it is a reasonable approximation of the in vivo
procedure, we cannot be certain. Plaque manipulation dur-
ing surgery may make it more susceptible to fracture.
Maximal balloon inflation pressures were used and while
PTFE has been shown to be similar to adventitia in com-
pliance it is only a simulation.We used self expanding stents
because of availability. These are not generally used in renal
angioplasty but balloon expanded stents also have been
shown to release large numbers of plaque fragments25
during ex vivo angioplasty, making this an unlikely source
of significant error. These, and other factors may have
caused the numbers of plaque fragments generated during
ex vivo angioplasty to be higher than in the clinical setting.
However, other factors, primarily our inability to account
for the additional atheroemboli generated by catheter ma-
nipulations within the aorta, may cause our numbers to be
too low. The exact numbers may be debated, but there is
little doubt that significant numbers of atheroemboli can be
released during renal angioplasty that could cause focal
areas of irreversible damage within the renal parenchyma.
Atheroembolization during clinical carotid angioplasty
has been documented by transcranical doppler studies as
well as clinical symptoms,39 and has prompted the use of
cerebral protection devices.40,41 Renal angioplasty using a
distal protection device has been reported in non-con-
trolled trials with excellent functional results.22,42 The au-
thors used commercially available filter baskets that have
approximately 100 m pore size. Additional clinical trials
will be needed. Furthermore, our data suggests that the
pore size of current cerebral protection devices may not be
sufficient. Ideally, a protection device is needed that would
lasty
20-40 m 40-60 m 60-100 m
,944 4,875  7,205 351  586 49  62
,705 2,587  3,299 162  287 60  90
,788 2,934  4,659 206  394 54  52
10,396 719 163
eries angioplasty with stent placement:
00-500 m 500-1000 m 1 mm
3.3  11.8 4.7  1.8 1.9  1.2
3.6  8.4 4.0  1.3 0.9  0.9
6.0  18.4 4.3  2.4 1.3  1.3
3.3  5.4 3.4  2.3 1.1  1.1
1.4  32.3 14.8  6.0 4.8  2.0giop
20 m
 30
 18
 20l art
2
2
1
1
1prevent the embolization of atherosclerotic fragments less
JOURNAL OF VASCULAR SURGERY
June 20051030 Hiramoto et althan 100m to prevent embolization of fragments that can
occlude the afferent arteriole and/or glomerulus.
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